Novartis Institute for Biomedical Research (NIBR)
IDEAYA has an exclusive license with Novartis Institute for Biomedical Research pursuant to which IDEAYA is developing and commercializing IDE196, a Phase 1 protein kinase C (PKC) inhibitor for the treatment of cancers having GNAQ and GNA11 mutations. IDE196 is a potent small molecule inhibitor of PKC demonstrating early clinical activity and tolerability in an ongoing NIBR Phase 1 single agent arm for patients with metastatic uveal melanoma (MUM). IDE196 is also being evaluated by NIBR in a combination arm of the trial with Novartis’ HDM201, for MUM patients. Under the license, NIBR will continue the ongoing clinical trial. IDEAYA has exclusive rights for further clinical development of IDE196, together with unrestricted rights to commercialize worldwide.
Cancer Research UK
IDEAYA has established a partnership with the Drug Discovery Unit at Cancer Research UK (CRUK) related to its Poly(ADP-ribose) glycohydrolase (PARG) program. Through an agreement signed in 2017, IDEAYA gained access to multiple proprietary series of small molecule inhibitors of PARG. IDEAYA and CRUK have expanded upon CRUK’s initial work, and the result of this collaborative effort has been the identification of potent, selective inhibitors of PARG.
University of California San Diego
Building a sustainable pipeline of high value synthetic lethality (SL) based oncology programs is central to the IDEAYA mission. To compliment the internal efforts around target identification and validation we have an ongoing collaboration with Dr. Trey Ideker PhD Professor of Medicine and Bioengineering, UCSD. Dr. Ideker is a recognized leader in combining functional genomics and computational methods to understand gene-gene and pathway interactions at a “systems” level. Under a collaborative agreement, the Ideker Lab and IDEAYA are carrying out combinatorial CRISPR screens of key nodes of the DNA damage and repair pathway and human tumor suppressor genes, to identify next generation druggable SL targets.
University of California San Francisco
IDEAYA is engaged in collaborative research with UCSF, which forms part of its strategic network for discovery and validation of biomarkers. Dr. Sourav Bandyopadhyay, PhD, is an Associate Professor in the Department of Bioengineering and Therapeutic Sciences of the Helen Diller Family Comprehensive Cancer Center at UCSF. Dr. Bandyopadhyay and IDEAYA are collaborating to identify and validate novel synthetic lethal relationships.